- This double microinjected model carries both human cholesteryl ester transfer protein and human apolipoprotein B100 transgenes
- Exhibits human-like serum HDL/LDL distribution
- When fed a high fat, high cholesterol diet these mice develop foam cell accumulation underlying the endothelium and within the media, and have significantly more complex atherosclerotic lesions than control animals
- Useful for evaluating compounds to treat hypercholesterolemia or HDL/LDL cholesterol imbalance to reduce the risk of developing atherosclerosis
- Differs from model 1007 in that the CETP line used to generate this model has been backcrossed for an additional 6 generations to C57BL/6, thereby reducing genes from the SJL strain
Genetic Background: B6.SJL Background
The CETP-ApoB100 microinjected model was developed in the laboratory of David Grass at Xenogen Biosciences, now Taconic, by crossing the ApoB100 microinjected model with the CETP microinjected model. At Taconic, the CETP-ApoB100 model is produced by mating the hemizygous ApoB100 transgenic model (1004) with the homozygous CETP transgenic model (3715).
Wild type for Nnt mutation
Grass DS, Saini U, Felkner RH, Wallace RE, Lago WJP, Young SG, Swanson ME. (1995) Transgenic Mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. J Lipid Res, 36(5): 1082-1090.